Printer Friendly

MEDICURE EXPANDS INTELLECTUAL PROPERTY POSITION.

Medicure Inc. (TSX:MPH), Winnipeg, Manitoba, a cardiovascular drug discovery and development company, has been issued Patent No. 6,417,204 by the U.S. Patent Office. The patent protects the composition of several of Medicure's newly discovered therapeutics.

The patent includes a library of small molecule therapeutic candidates, called antithrombotics. Antithrombotics are substances that prevent blood factors (platelets and fibrin) from aggregating and subsequently blocking blood flow. These blockages cause various cardiovascular problems including heart attacks.

Antithrombotics have applications in various clinical indications ranging from the chronic prevention of stroke to acute treatment for heart attacks. The antithrombotic market can be broadly divided into three major classes: thrombolytics, anti-platelet agents and anticoagulants.

Thrombolytics are agents that dissolve or split up blood clots;

Antiplatelets are agents that prevent blood platelets from aggregating;

Anticoagulants are agents that prevent blood clotting.

"We are very pleased with the issuance of this patent as it will strengthen our position for any future licensing negotiations," stated Albert D. Friesen, PhD, president and CEO. "We believe that the potential for these small molecule candidates is significant."

Antithrombotics are a major part of drug discovery activity due to the large market size and the recognized need for new products within these markets. Medicure's antithrombotic program utilizes pharmacophore based drug design based on a unique scaffold to design a new class of therapeutics intended to offer improved treatment for cardiovascular needs.

About Medicure Inc.

Medicure Inc. is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine including the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke.

For more information, call (88)8435-2220 or (204)487-7412 or visit http://www.medicureinc.com.
COPYRIGHT 2002 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:1CANA
Date:Dec 1, 2002
Words:287
Previous Article:EXONHIT INITIATES PHASE II CLINICAL TRIAL FOR EHT 0201.
Next Article:BRITANNIA TO DEVELOP NASAL POWDER FOR MIGRAINE SUFFERERS.


Related Articles
MEDICURE GETS U.S. PATENT NOTICE OF ALLOWANCE FOR THERAPEUDICS.
MEDICURE APPROVED TO INITIATE PHASE II/III HYPERTENSION TRIALS.
MEDICURE GETS FDA/TPD APPROVALS FOR MC-1 PHASE II TRIAL.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters